Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMA-6: r-SAK Prior to Primary PCI in STEMI
NCT05410925Phase 4Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Apr 2023
- Primary completion
- Dec 2026
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in ST elevation myocardial infarction (STEMI) comparing r-SAK group with placebo group (2 arms). Primary endpoint: Major Adverse Cardiovascular Events at 90 days. Started Apr 2023; status: recruiting.
02
Drugs
staphylokinase
03
Conditions
ST elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT05410925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05410925.